SLC5A2 and hydrops fetalis: It is plausible that, in the near future, the ESC guidelines are supplemented with the results of the DELIVER and EMPEROR-PRESERVED trials and that the use of SGLT2 inhibitors is recommended in patients with HF regardless of LVEF.